CA2633501C - Immunoglobulins - Google Patents

Immunoglobulins Download PDF

Info

Publication number
CA2633501C
CA2633501C CA2633501A CA2633501A CA2633501C CA 2633501 C CA2633501 C CA 2633501C CA 2633501 A CA2633501 A CA 2633501A CA 2633501 A CA2633501 A CA 2633501A CA 2633501 C CA2633501 C CA 2633501C
Authority
CA
Canada
Prior art keywords
seq
antibody
nogo
antibodies
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2633501A
Other languages
English (en)
French (fr)
Other versions
CA2633501A1 (en
Inventor
Stephanie Jane Clegg
Jonathan Henry Ellis
Volker Germaschewski
Paul Andrew Hamblin
George Kopsidas
Ruth Mcadam
Rabinder Kumar Prinjha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2633501(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CA2633501A1 publication Critical patent/CA2633501A1/en
Application granted granted Critical
Publication of CA2633501C publication Critical patent/CA2633501C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2633501A 2005-12-16 2006-12-14 Immunoglobulins Expired - Fee Related CA2633501C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
GB0525662.3 2005-12-16
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (2)

Publication Number Publication Date
CA2633501A1 CA2633501A1 (en) 2007-06-21
CA2633501C true CA2633501C (en) 2015-03-31

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2633501A Expired - Fee Related CA2633501C (en) 2005-12-16 2006-12-14 Immunoglobulins

Country Status (30)

Country Link
US (2) US8362208B2 (https=)
EP (2) EP2228391A3 (https=)
JP (1) JP5015949B2 (https=)
KR (1) KR101355118B1 (https=)
CN (1) CN101374863B (https=)
AR (1) AR057239A1 (https=)
AU (1) AU2006325228B2 (https=)
BR (1) BRPI0619855A2 (https=)
CA (1) CA2633501C (https=)
CR (1) CR10099A (https=)
CY (1) CY1113094T1 (https=)
DK (1) DK1960429T3 (https=)
EA (1) EA015536B1 (https=)
ES (1) ES2389380T3 (https=)
GB (1) GB0525662D0 (https=)
HR (1) HRP20120684T1 (https=)
IL (1) IL192086A0 (https=)
JO (1) JO2795B1 (https=)
MA (1) MA30041B1 (https=)
MY (1) MY149492A (https=)
NO (1) NO20082699L (https=)
NZ (1) NZ569143A (https=)
PE (1) PE20071099A1 (https=)
PL (1) PL1960429T3 (https=)
PT (1) PT1960429E (https=)
SI (1) SI1960429T1 (https=)
TW (1) TWI378940B (https=)
UA (1) UA96279C2 (https=)
WO (1) WO2007068750A2 (https=)
ZA (2) ZA200805111B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004831A (es) * 2007-11-02 2010-05-21 Novartis Ag Moleculas de enlace de nogo-a mejoradas y uso farmaceutico de las mismas.
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
EP2271323A2 (en) 2008-05-06 2011-01-12 Glaxo Group Limited Encapsulation of biologically active agents
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
AU2013285493A1 (en) 2012-07-05 2015-01-22 Glaxo Group Limited Optimum dose regime of an anti-Nogo-A antibody in the treatment of amyotrophic lateral sclerosis
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US11013815B2 (en) 2017-06-14 2021-05-25 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
MX2021015473A (es) * 2019-06-13 2022-04-20 Prestige Biopharma Pte Ltd Nuevo anticuerpo específico para cthrc1 y su uso.
US20230399390A1 (en) 2019-10-24 2023-12-14 Novago Therapeutics Ag Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
JP2024526122A (ja) 2021-06-17 2024-07-17 ペットメディックス・リミテッド 抗イヌｃｄ２０抗体
EP4419547A1 (en) 2021-10-21 2024-08-28 Petmedix Ltd. Proteins comprising the extracellular domain of p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
KR20240139085A (ko) 2022-02-09 2024-09-20 펫메딕스 리미티드 치료 항체
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
KR20250141832A (ko) 2023-02-09 2025-09-29 펫메딕스 리미티드 P75 뉴로트로핀 수용체(p75ntr)의 세포외 도메인 변이체를 포함하는 치료 분자
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
SK282721B6 (sk) 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1997001352A1 (en) 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002522016A (ja) 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
CN101684155A (zh) 1998-11-06 2010-03-31 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
EP2213684A3 (en) * 2003-12-22 2011-05-18 Glaxo Group Limited Nogo-a antibodies for the treatment of Alzheimer disease
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
EP2228391A2 (en) 2010-09-15
WO2007068750A3 (en) 2007-11-29
BRPI0619855A2 (pt) 2011-10-25
NZ569143A (en) 2011-08-26
HK1119720A1 (en) 2009-03-13
SI1960429T1 (sl) 2012-09-28
JP2009519025A (ja) 2009-05-14
PL1960429T3 (pl) 2012-11-30
EA200801343A1 (ru) 2008-12-30
US20100221260A1 (en) 2010-09-02
ZA200805111B (en) 2009-12-30
PE20071099A1 (es) 2007-11-22
JP5015949B2 (ja) 2012-09-05
AU2006325228B2 (en) 2011-12-15
CN101374863A (zh) 2009-02-25
US20130287781A1 (en) 2013-10-31
HRP20120684T1 (hr) 2012-09-30
AU2006325228A1 (en) 2007-06-21
MA30041B1 (fr) 2008-12-01
IL192086A0 (en) 2008-12-29
EP2228391A3 (en) 2010-12-29
US8362208B2 (en) 2013-01-29
ES2389380T3 (es) 2012-10-25
TWI378940B (en) 2012-12-11
NO20082699L (no) 2008-09-08
TW200801038A (en) 2008-01-01
CA2633501A1 (en) 2007-06-21
CY1113094T1 (el) 2016-04-13
JO2795B1 (en) 2014-03-15
DK1960429T3 (da) 2012-09-24
CN101374863B (zh) 2013-05-29
MY149492A (en) 2013-09-13
ZA200906162B (en) 2010-05-26
PT1960429E (pt) 2012-09-25
CR10099A (es) 2008-09-22
GB0525662D0 (en) 2006-01-25
WO2007068750A2 (en) 2007-06-21
EP1960429B1 (en) 2012-06-27
KR20080080644A (ko) 2008-09-04
EP1960429A2 (en) 2008-08-27
EA015536B1 (ru) 2011-08-30
KR101355118B1 (ko) 2014-02-06
UA96279C2 (ru) 2011-10-25
AR057239A1 (es) 2007-11-21

Similar Documents

Publication Publication Date Title
US20130287781A1 (en) Immunoglobulins
US7780964B2 (en) Immunoglobulins which bind NOGO
MX2008012483A (es) Anticuerpos contra peptido beta-amiloide.
JP5922592B2 (ja) 血清アミロイドｐ成分に特異的な抗原結合タンパク質
IL188282A (en) Monoclonal antibody that binds and neutralizes human nogo, a pharmaceutical composition comprising it and uses thereof
CN101258165B (zh) Nogo-a对人抗体有特效和它的药学应用
US9434716B2 (en) Antigen binding proteins
HK1142344A (en) Immunoglobulins directed against nogo
HK1119720B (en) Immunoglobulins directed against nogo
HK1115598B (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181214